A randomised, double-blind, parallel-group comparison of the efficacy and the safety of venlafaxine versus nortriptyline in the treatment of depressed elderly inpatients

Submission date 16/05/2005	Recruitment status No longer recruiting	Prospectively registered
		☐ Protocol
Registration date 16/05/2005	Overall study status Completed	Statistical analysis plan
		[X] Results
Last Edited 02/04/2008	Condition category Mental and Behavioural Disorders	[] Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Rob M. Kok

Contact details

Altrecht GGZ
Jutfaseweg 205
Utrecht
Netherlands
3522 HR
+31 (0)30 2297600
r.kok@altrecht.nl

Additional identifiers

Protocol serial number NTR27

Study information

Scientific Title

Study objectives

Venlafaxine and nortriptyline are not significantly different in efficacy in elderly inpatients with depression but venlafaxine is better tolerated.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the local medical ethics committee

Study design

Randomised, double blind, active controlled, parallel group trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Depressive disorders

Interventions

- 1. Nortriptyline (range 25 200 mg)
- 2. Venlafaxine (range 75 300 mg)

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Venlafaxine, nortriptyline

Primary outcome(s)

Remission on the MADRS (final score of 10 or less).

Key secondary outcome(s))

- 1. Remission on Hamilton Depression rating scale (HAM-D) and Geriatric Depression Scale (GDS)
- 2. Response on MADRS, HAM-D and GDS
- 3. Number of side effects
- 4. Global Tolerability Score
- 5. MMSE
- 6. Barthel Activities of Daily Living (ADL) score
- 7. 20-item Short Form health survey (SF-20)

Completion date

01/12/2004

Eligibility

Key inclusion criteria

- 1. Male or female inpatient
- 2. Aged 60 years or older
- 3. Meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for:
- 3.1. Major depression, single or recurrent episode (296.2x, 296.3x)
- 3.2. Dysthymic disorder (300.4)
- 3.3. Mood disorder due to a general medical condition, with depressive features or with major depressive-like episode (293.83)
- 3.4. Substance induced mood disorder with depressive features (292.84)
- 3.5. Depressive disorder not otherwise specified (i.e. minor depressive disorder) (311)
- 4. Have a baseline Montgomery-Asberg Depression Rating Scale (MADRS) total score greater than or equal to 20
- 5. Have a baseline Mini-Mental State Examination (MMSE) score greater than 15
- 6. Written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Senior

Sex

All

Key exclusion criteria

- 1. Known hypersensivity to venlafaxine or nortriptyline
- 2. Previous unsuccessful treatment with venlafaxine for at least 4 weeks with a minimum dose of 75 mg/day or previous unsuccessful treatment with nortriptyline for at least 4 weeks with a serum level within the therapeutic range
- 3. Relevant medical illness which is a contra-indication for the use of the study medication, such as myocardial infarction within previous 6 months
- 4. Use of electroconvulsive therapy (ECT) within 30 days prior to baseline, use of a monoamine oxidase (MAO) inhibitor within 14 days, use of fluoxetine within 21 days, use of any antidepressant drug (except those allowed during the study as concomitant treatment) within 3 days prior to baseline
- 5. Alcohol or drug abuse within the last year, according to DSM-IV criteria
- 6. Presence of dementia, or a non-affective psychotic disorder, or a history of bipolar disorder (I and II), all according to DSM-IV criteria

Date of first enrolment

01/10/1999

Date of final enrolment

01/12/2004

Locations

Countries of recruitment

Netherlands

Study participating centre Altrecht GGZ

Utrecht Netherlands 3522 HR

Sponsor information

Organisation

Altrecht GGZ (The Netherlands)

ROR

https://ror.org/050jqep38

Funder(s)

Funder type

Industry

Funder Name

Wyeth Pharmaceuticals B.V. (The Netherlands) (ref: 100186)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Results article Results 01/12/2007

2007

Yes

No